Strategic partnerships Novasep has a history of forming manufacturing, development, and asset-partnering deals with major pharma players (Exelixis, Pfizer) and mergers (PharmaZell), indicating openness to collaborative CDMO arrangements that could be expanded for additional high-potency APIs, ADCs, and cGMP clinical production opportunities.

HPAPI and ADC focus The company highlights leadership in high-potency APIs and antibody-drug conjugates, supported by a broad purification and process engineering toolbox, suggesting strong cross-sell potential into advanced oncology programs, biologics-conjugates, and complex small-molecule/bioconjugate projects.

Global footprint With R&D labs and pilot plants across the US, Europe, and Asia, and multiple sites in France, Novasep can support regional manufacturing scale-up, technology transfer, and supply chain diversification for multinational clients seeking nearshore/offshore options.

Expansion readiness Recent and ongoing site investments in Mourenx and Chasse-sur-Rhône to expand API and HPAPI capacity indicate capacity expansion and modernization, creating upsell opportunities for additional CDMO services, revamps, and turnkey production contracts.

Diverse end-market reach Serving pharmaceutical innovators, natural products, cosmetics ingredients, and agrochemicals, Novasep presents cross-vertical selling angles for broadened contracts, from small molecule APIs to biomolecules and purification services across multiple life-science sectors.